Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
78 hedge funds and large institutions have $220M invested in Eiger BioPharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
73% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 15
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
24% more funds holding
Funds holding: 63 → 78 (+15)
2% more capital invested
Capital invested by funds: $215M → $220M (+$4.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$16.9M |
| 2 |
BlackRock
New York
|
+$14.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.3M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$11.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$33.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.3M |
| 3 |
Millennium Management
New York
|
-$2.97M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.59M |
| 5 |
Barclays
London,
United Kingdom
|
-$636K |
EIGR Hedge Fund Activity: Q2 2019 in Review
78 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2019, worth a combined $220M — up 1.9% from $215M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new EIGR positions and 10 closed out — a net gain of 15 holders — while 26 added to existing stakes and 15 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $16.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $33.8M sold.
- 78 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2019, up from 63 in Q1 2019.
- Funds reported $220M of Eiger BioPharmaceuticals, Inc. stock for Q2 2019, up 1.9% quarter-over-quarter.
- 25 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2019 and 10 closed out, a net change of +15 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2019 was Broadfin Capital, an estimated $16.9M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2019 was RA Capital Management, an estimated $33.8M sold.
Based on aggregated 13F filings for Q2 2019.